The aim of a current examine shared on the 2025 World Convention on Lung Most cancers was to guage THIO (ateganosine, 6-thio-2’-deoxyguanosine), a telomerase inhibitor, together with immunotherapy for superior non-small cell lung most cancers, defined Dr. Thomas Jankowski, a medical oncologist on the Medical College of Lubin in Poland.
Jankowski famous that whereas checkpoint inhibitors have proven sturdy leads to general and progression-free survival, many sufferers nonetheless expertise illness development, with chemotherapy being the one authorised second-line choice. THIO is being examined at very small doses not for its chemotherapy impact, however to assist overcome resistance to checkpoint inhibitors.
On this examine, THIO is being mixed with Libtayo(cemiplimab), although Jankowski emphasised that it might probably be paired with different PD-1 or PD-L1 inhibitors as properly.
Transcript
What was the primary goal of this examine, THIO and Libtayoin superior non-small cell lung most cancers?
We reside in an period of immunotherapy with checkpoint inhibitors, which have proven excellent outcomes, together with lengthy general survival and progression-free survival. Nonetheless, some sufferers nonetheless expertise illness development. Presently, second-line remedy for these sufferers is just chemotherapy. There is no such thing as a established immunotherapy after immunotherapy but, though many trials are specializing in this. Proper now, we don’t have immunotherapy choices for sufferers who progress after prior immunotherapy, so we’re searching for new medication, particularly for sufferers in second, third or later strains of remedy.
Our drug, THIO, is a telomerase inhibitor. It’s a sort of chemotherapy, however in our mission, we use solely very restricted, small doses. We use THIO not for its chemotherapy impact, however to beat resistance to immunotherapy with checkpoint inhibitors. That’s the reason we mix THIO with immunotherapy in our trial.
We use Libtayoas one of many immunotherapy medication as a result of now we have a collaboration with its producer. Nonetheless, I consider it might be mixed with any immunotherapy drug, both anti-PD-1 or anti-PD-L1. We even have trials in different cancers utilizing completely different immune checkpoint inhibitors. On this trial, we’re utilizing Libtayo.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
